 | • レポートコード：B-MOR-05380 • 出版社/出版日：Mordor Intelligence / 2018年3月 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：Healthcare |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、小分子薬剤の創薬の世界市場について調べ、小分子薬剤の創薬の世界規模、市場動向、市場環境、治療領域別分析、段階別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・小分子薬剤の創薬の世界市場インサイト ・小分子薬剤の創薬の世界市場環境 ・小分子薬剤の創薬の世界市場動向 ・小分子薬剤の創薬の世界市場規模 ・小分子薬剤の創薬の世界市場規模：治療領域別 ・小分子薬剤の創薬の世界市場規模：段階別 ・小分子薬剤の創薬の世界市場：地域別市場規模・分析 ・小分子薬剤の創薬の北米市場規模・予測 ・小分子薬剤の創薬のアメリカ市場規模・予測 ・小分子薬剤の創薬のヨーロッパ市場規模・予測 ・小分子薬剤の創薬のアジア市場規模・予測 ・小分子薬剤の創薬の日本市場規模・予測 ・小分子薬剤の創薬の中国市場規模・予測 ・小分子薬剤の創薬のインド市場規模・予測 ・小分子薬剤の創薬の韓国市場規模・予測 ・関連企業情報・競争状況 |
The global small molecule drug discovery market is expected to witness a CAGR of 6.8% during the forecast period (2018-2023). North America dominates the market due to a rise of chronic disease in that region.
Rise in Demand for Small Molecule Drugs
Small molecule drugs accounted for 84% of the total pharmaceutical industry revenue in 2014. In 2015, a total of 45 new molecular entities were approved in the United States, out of which 33 were small molecules. The versatility of small molecule drugs, which can range from global blockbusters to targeted therapies to orphan drugs, and their ability to be formulated into pills and tablets are driving the demand for these drugs. There has been an increase in the number of Contract Development and Manufacturing Organizations (CDMO) entering the pharmaceutical industry. CDMOs that focus on the development of small molecules are experiencing a significant growth in the industry. In 2015, the revenues of Contract Research Organizations (CROs) and CDMOs, focusing on the development of small molecules, increased by 15-20%. CROs and CDMOs play a critical role in the drug discovery process as most of the key development activities are achieved by outsourcing them to contract organizations. The resultant rise in demand for small molecule drug will drive the market in forecast years.
Additionally, the dominance of small molecules in the market, small molecules in the treatment of chronic diseases, and the high R&D expenditure on small molecule drugs are fuelling the growth of global small molecule drug discovery market.
High Drug Development Cost
On an average, the cost of drug development scales between USD 1.5-3 billion and averages around USD 2.6 billion. This high cost of drug development is a result of the high failure rate of experiments and a relatively lower efficiency figures involved in the initial phases of drug discovery. As per data reported by Centers for Medicare & Medicaid Services in December 2015, drug development cost for Medicare’s Sovaldi was around USD 3.1 billion, and for Nexium, the figure was close to USD 2.6 billion. Most of the small molecule drug discovery cost lies in the same bracket. Thus, developing such drugs always involves high costs, which cannot be borne by new entrants or small-scale laboratories, this is limiting the market scope.
Additionally, strict regulations are also restraining the growth of global small molecule drug discovery market.
Key Developments in the Market
• December 2017: Pfizer entered into an agreement to Develop and Commercialize CRESEMBA® (isavuconazole) in China and Asia-Pacific Region.
• December 2017: Teva Pharmaceutical launched a generic version of Viread that is used for the treatment of HIV-1 infection in adults and pediatric patients
Major Players: PFIZER INC., BRISTOL- MYERS SQUIBB, MERCK & CO., BOEHRINGER INGELHEIM GMBH, GLAXOSMITHKLINE, ASTRAZENECA, JOHNSON & JOHNSON, GILEAD SCIENCES INC., and TEVA PHARMACEUTICALS, amongst others.
Reasons to Purchase this Report
• Current and future small molecule drug discovery market outlook in the developed and emerging markets
• Analyzing various perspectives of the market with the help of Porter’s five forces analysis
• Identifying the segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3-month analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porters Five Forces
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Driver
6.1.1 Rise in Demand for Small Molecule Drugs
6.1.2 Dominance of Small Molecules in the Market
6.1.3 Increasing Number of Contract Organizations for R&D
6.1.4 Small Molecules in Treatment of Chronic Diseases
6.1.5 High R&D Expenditure in Small Molecule Drugs
6.2 Market Restraints
6.2.1 High Drug Development Cost
6.2.2 Strict Regulations
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Therapeutic Area
7.1.1 Oncology
7.1.2 Central Nervous System
7.1.3 Cardiovascular
7.1.4 Respiratory
7.1.5 Metabolic
7.1.6 Gastrointestinal
7.1.7 Orthopedics
7.1.8 Anti-Infective
7.1.9 Dermatology
7.1.10 Immunological
7.1.11 Others
7.2 By Process Phase
7.2.1 Target Id/Validation
7.2.2 Hit Generation and Selection
7.2.3 Lead Identification
7.2.4 Lead Optimization
7.3 By Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United Kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia & New Zealand
7.3.3.5 South Korea
7.3.3.6 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest of Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations & Partnerships
8.3 New Products Launches
9. Company Profiles
9.1 Pfizer Inc
9.2 Bristol- Myers Squibb
9.3 Merck & Co.
9.4 Boehringer Ingelheim Gmbh
9.5 Glaxosmithkline
9.6 Astrazeneca
9.7 Johnson & Johnson
9.8 Gilead Sciences, Inc.
9.9 Teva Pharmaceuticals
10. Future Outlook of the Market